Darbepoetin alfa clinical trials
Also written Aranesp, Darbepoetin and BCD-066.
How each study uses Darbepoetin alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Darbepoetin alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Sept 2001 · ARANESP · BLA 103951 (FDA, Drugs@FDA)
- European Union
- 8 Jun 2001 · Aranesp · EMEA/H/C/000332 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
117 studies that test it; most in 2002 (20)
| Year | Studies |
|---|---|
| 1999 | 2 |
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 20 |
| 2003 | 12 |
| 2004 | 15 |
| 2005 | 7 |
| 2006 | 12 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 74 · Other 51
Amgen (62) · Biocad (3) · Kyowa Kirin Co., Ltd. (3) · University of New Mexico (2) · M.D. Anderson Cancer Center (2) · Seoul National University Bundang Hospital (2) · University of Washington (2) · Institute of Liver and Biliary Sciences, India (2)
Often tested with
Tested in the same studies.
Pegfilgrastim (4) · Epoetin Alfa (4) · Roxadustat (2) · Canakinumab (1) · Filgrastim (1) · Paricalcitol (1) · R-CHOP Regimen (1) · Doxorubicin (1)
Related medicines
As reviewed, each with the page that says it.
- A recombinant medicine of Erythropoietin source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Darbepoetin alfa is the comparator. A study of two new drugs counts under both.
- 1GSK1278863 · Qilu Pharmaceutical Co., Ltd. · next primary completion May 2027
- 1Efepoetin alfa · Genexine, Inc. · next primary completion Jun 2027
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test Darbepoetin alfa, phase 3 first.
- Dec 2026Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)Phase 3 · Fundacion Clinic per a la Recerca Biomédica
- Dec 2026Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.Not applicable · Institute of Liver and Biliary Sciences, India
- Jan 2027The Effect of Roxadustat on Renal Oxygenation in Diabetes NephropathyPhase 2 · Region Stockholm
- Jan 2027Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm InfantsPhase 2 · University of Washington
Studies
Open first, then newest update. How each study uses Darbepoetin alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 125
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm InfantsRecruitingPhase 2University of WashingtonNCT05340465Written as Darbepoetin AlfaHow we know
- Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.RecruitingNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT07002827Written as DarbepoetinHow we know
- Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesEnrolling by invitationNot applicableEnhanced Emirates LimitedNCT07568574Written as EPO Darbepoetin (Aranesp)How we know
- Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)RecruitingPhase 3Fundacion Clinic per a la Recerca BiomédicaNCT07169643Written as Darbepoetin (DP)How we know
- National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated CirrhosisNot yet recruitingNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT07131280Written as DarbepoetinHow we know
- The Effect of Roxadustat on Renal Oxygenation in Diabetes NephropathyNot yet recruitingPhase 2Region StockholmNCT05810311Written as Darbepoietin AlfaHow we know
- Darbepoetin in Neonatal Encephalopathy TrialRecruitingPhase 2Imperial College LondonNCT04432662Written as Darbepoetin AlfaHow we know
- Darbepoetin for Ischemic Neonatal Stroke to Augment RegenerationCompletedPhase 2UMC UtrechtNCT03171818Written as Darbepoetin AlfaHow we know
- Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm InfantsCompletedPhase 3NICHD Neonatal Research NetworkNCT03169881Written as DarbepoetinHow we know
- Mechanisms of EPO-induced HypertensionTerminatedPhase 2VA Office of Research and DevelopmentNCT03810911Written as DarbepoetinHow we know
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAActive, not recruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT04798339Written as Darbepoetin AlfaHow we know
- Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 StudyActive, not recruitingPhase 4Gangnam Severance HospitalNCT07025460Written as darbepoetin alfaHow we know
- Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic SyndromesCompletedPhase 3Barts & The London NHS TrustNCT01196715Written as Darbepoetin alphaHow we know
- A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With AnemiaCompletedPhase 3Astellas Pharma IncNCT02952092Written as Darbepoetin alfaHow we know
- Darbe Administration in Newborns Undergoing Cooling for EncephalopathyCompletedPhase 1/2University of UtahNCT01471015Written as Darbepoetin alfaHow we know
- Mild Encephalopathy in the Newborn Treated With DarbepoetinCompletedPhase 2University of New MexicoNCT03071861Written as Darbepoetin AlfaHow we know
- Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast CancerCompletedPhase 2Harold J. Burstein, MD, PhDNCT00146562Written as Darbepoetin AlfaHow we know
- Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ChemotherapyTerminatedPhase 3AmgenNCT00858364Written as Darbepoetin alfaHow we know
- Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney DiseaseTerminatedPhase 3AmgenNCT00436748Written as Darbepoetin AlfaHow we know
- RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialCompletedPhase 3AmgenNCT00358215Written as Darbepoetin alfaHow we know
See all 125 studies that test Darbepoetin alfa →
Given beside what is tested · 7 — Darbepoetin alfa is usual care or a partner of the new treatment
- Combination Therapy of Romiplostim and Erythropoiesis-stimulating AgentsRecruitingPhase 2Chinese University of Hong KongNCT07854561Written as darbepoetin alfaHow we know
- Luspatercept + Darbepoetin in MDSRecruitingPhase 2Yale UniversityNCT07096297Written as DarbeopoetinHow we know
- High Dose IV Iron Plus ESA in Chemotherapy-induced AnemiaRecruitingPhase 3Hallym University Medical CenterNCT05768997Written as Darbepoetin Alfa InjectionHow we know
- Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell LymphomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00058422Written as darbepoetin alfaHow we know
- A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)CompletedPhase 4Hoffmann-La RocheNCT00773513Written as Darbepoetin AlfaHow we know
- Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)CompletedPhase 4University Hospital, Basel, SwitzerlandNCT01306409Written as cera, darbepoetin, epoetin-betaHow we know
- Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedPhase 3Mayo ClinicNCT00661999Written as darbepoetin alfaHow we know
As the comparator · 49 — what is tested is compared with Darbepoetin alfa
- A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisRecruitingPhase 3Genexine, Inc.NCT06466785Written as Darbepoetin AlfaHow we know
- A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)Not yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07300111Written as Darbepoetin alfaHow we know
- Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03329196Written as Darbepoetin alfaHow we know
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03439137Written as Darbepoetin alfaHow we know
- Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)CompletedPhase 3Akebia TherapeuticsNCT04313153Written as Darbepoetin alfaHow we know
- Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable DialysisCompletedPhase 3Astellas Pharma Europe B.V.NCT02278341Written as Darbepoetin alfaHow we know
- Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin AlfaCompletedPhase 3Astellas Pharma Europe B.V.NCT02021318Written as Darbepoetin alfaHow we know
- A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference DrugCompletedPhase 2Astellas Pharma IncNCT01888445Written as darbepoetin alfaHow we know
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)CompletedPhase 3GlaxoSmithKlineNCT02876835Written as Darbepoetin alfaHow we know
- Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)TerminatedPhase 2GlaxoSmithKlineNCT03446612Written as Darbepoetin alfaHow we know
- Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male VolunteersCompletedPhase 4Yi FangNCT05864261Written as NESP 60ugHow we know
- Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedPhase 3Akebia TherapeuticsNCT02865850Written as Darbepoetin alfaHow we know
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedPhase 3Akebia TherapeuticsNCT02892149Written as Darbepoetin alfaHow we know
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)CompletedPhase 3Akebia TherapeuticsNCT02680574Written as Darbepoetin alfaHow we know
- Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney DiseaseCompletedPhase 3Akebia TherapeuticsNCT02648347Written as Darbepoetin alfaHow we know
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)CompletedPhase 3GlaxoSmithKlineNCT03029208Written as Darbepoetin alfaHow we know
- A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.CompletedPhase 3Hoffmann-La RocheNCT00717821Written as Darbepoetin AlfaHow we know
- A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.CompletedPhase 3JW PharmaceuticalNCT04027517Written as Darbepoetin AlfaHow we know
- Maintenance Treatment of Renal Anemia in Dialysis SubjectsCompletedPhase 3BayerNCT03543657Written as Darbepoetin alfaHow we know
- A Study of Molidustat for Correction of Renal Anemia in Non-dialysis SubjectsCompletedPhase 3BayerNCT03350321Written as Darbepoetin alfaHow we know
Showing 20 of 49.
Codes
What other systems call Darbepoetin alfa · ClinicalTrials.gg INT006503
- MeSH (NLM) D000068256Darbepoetin alfaConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 15UQ94PT4PDARBEPOETIN ALFAConfirmed FDA, NLM, Wikidata
- RxNorm 283838Confirmed FDA, Wikidata
- Wikidata Q2178381darbepoetin alfaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1878Darbepoetin AlfaOne source FDA
- DrugBank DB00012One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068256 | Darbepoetin alfa | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 15UQ94PT4P | DARBEPOETIN ALFA | Confirmed FDA, NLM, Wikidata |
| RxNorm | 283838 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2178381 | darbepoetin alfa | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1878 | Darbepoetin Alfa | One source FDA |
| DrugBank | DB00012 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.